Today: 11 June 2026
Vodafone shares near £1 as buyback filing hits and valuation debate sharpens
31 December 2025
1 min read

Vodafone shares near £1 as buyback filing hits and valuation debate sharpens

NEW YORK, December 31, 2025, 03:53 ET

  • Vodafone shares traded around 99 pence on Wednesday, hovering just below the £1 mark.
  • Vodafone said it repurchased 12.38 million shares in its latest tranche of an ongoing buyback programme.
  • A Simply Wall St analysis published last week put fair value below the recent close and showed most analyst price targets under £1.

Vodafone shares hovered just below the £1 level on Wednesday, trading at about 99.22 pence in London, as the telecoms group continued a steady run of share buybacks into year-end.

The move matters because the one-pound mark is a psychological threshold for retail and institutional investors in the U.K., where Vodafone is a heavyweight in the FTSE 100.

It also comes as trading volumes thin out around the holidays, making price levels and corporate buying programmes more visible in daily market moves.

In a regulatory filing on Tuesday, Vodafone said it repurchased 12,383,048 ordinary shares on Dec. 29 at prices between 96.60 pence and 98.02 pence, paying a volume-weighted average price of 97.62 pence. A buyback is when a company repurchases its own shares; treasury shares are typically not entitled to dividends and carry no voting rights.

Vodafone said it would hold the shares in treasury, taking its treasury holdings to 1,352,076,203 shares, with 23,525,884,554 shares in issue excluding treasury stock, the filing showed.

The stock ended Tuesday at 98.54 pence and remained about 10% below its 52-week high of £1.09 set on Dec. 19, MarketWatch data showed.

A Yahoo Finance UK column published this week said Vodafone was trading close to its 2025 highs and “might only be weeks” from reaching the £1 level. https://uk.finance.yahoo.com/news/forecast…

Not everyone sees more upside at current levels. In an analysis published Dec. 22, Simply Wall St said its most-followed “narrative” put Vodafone’s fair value at about 90 pence, and cited a consensus analyst price target of £0.858, with estimates ranging from £0.60 to £1.36. https://simplywall.st/stocks/gb/telecom/ls…

The same analysis said Vodafone traded at about 0.7 times sales versus an “industry average” closer to 1.6 times, suggesting the market still prices in execution risk even after the recent rally.

Simply Wall St also pointed to weak execution in Germany and the complexity of large-scale restructuring as factors that could derail margin improvements assumed by more optimistic forecasts.

Vodafone competes with BT Group’s EE and Hutchison’s Three in the U.K. market, and faces European rivals including Orange and Telefónica across its footprint.

Stock Market Today

  • Ford Stock Down 6% Over Five Years Amid Strategic Shift
    June 11, 2026, 10:58 AM EDT. Ford's stock has fallen 6% over five years, significantly underperforming the S&P 500's 71% gain despite a recent 20% rally. The company exited costly electric vehicle (EV) programs, launching Ford Energy to produce lithium-ion phosphate batteries for energy storage through a partnership with China's CATL. Investors remain cautious, focusing on Ford's reliance on domestic sales of its F-Series gas-powered trucks, its longstanding best-seller. Ford's strategic pivot away from EVs, admitting Chinese EV competition risks, and modest international presence contribute to lingering investor skepticism about its long-term value.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
Newmont stock rebounds as gold steadies after CME margin jolt; Raymond James lifts target
Previous Story

Newmont stock rebounds as gold steadies after CME margin jolt; Raymond James lifts target

Premium Bonds January 2026 draw date is set — here’s when NS&I results drop and why savers are rethinking
Next Story

Premium Bonds January 2026 draw date is set — here’s when NS&I results drop and why savers are rethinking

Go toTop